CV Technologies
This article was originally published in The Tan Sheet
Executive Summary
Canadian biopharmaceutical firm announces U.S. FDA clearance of investigational new drug application for CVT-E002, a North American ginseng extract intended for use as a prophylactic against acute respiratory infection. Recruiting of 200 frail, older adults from nursing homes will begin shortly for a four-month, Phase II clinical trial conducted by Eastern Virginia Medical School in Norfolk. CVT's six FX dietary supplement products are marketed in the U.S. by Amrion, a division of Whole Foods, and are sold in Canada under the HerbTech name. CVT has approximately 80 dietary supplement and five Rx products in the pipeline and is seeking alliances with pharmaceutical firms